Homepage Top Section1

The company-sponsored study is being carried out in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and

As per terms of the deal, Sage will secure $1.525 in cash that includes an upfront payment of $875m and $650m equity investment, as well as potential milestone

Xofluza, a first-in-class and single-dose medicine, has showed efficacy in a range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in

RSV is responsible for respiratory infections such as bronchiolitis and viral pneumonia in infants. It is estimated that in the world, 33 million cases of RSV occur in

The high-level results from an interim analysis, including 131 Covid-19, have shown no hospitalisations or severe cases of the disease in participants receiving the vaccine. AZD1222, co-invented by

The data analysis showed a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (primary infection), as well as in participants with and without prior SARS-CoV-2

The phase 2 segment will evaluate the efficacy of Covid-19 DNA vaccine candidate called INO-4800 in adults in the US. Inovio’s study will be financed by the US

As part of single target research collaboration, both companies will conduct research activities to select a pre-clinical candidate after which Roche will focus on further development and global

The interim analysis showed that Sputnik V vaccine has shown an efficacy rate of 92% after the second dose in the patients. Sputnik V vaccine is based on